Zobrazeno 1 - 7
of 7
pro vyhledávání: '"J Toennesen"'
Autor:
J Toennesen, J P Pallisgaard, P V R Rasmussen, M R Ruwald, C Z Zoerner, L R V Riis-Vestergaard, C M Middelfart, G G Gislason, M L H Hansen
Publikováno v:
Europace. 25
Funding Acknowledgements Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): Novo Nordisk Introduction Both atrial fibrillation (AF) and obesity have reached epidemic proportions. Obesity is an established risk facto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::18d7313d62c2103d3339da28ba135738
https://doi.org/10.1093/europace/euad122.029
https://doi.org/10.1093/europace/euad122.029
Autor:
C R Zoerner, J P Pallisgaard, A M Schjerning, M K Jensen, J Toennesen, L D Riis-Vestergaard, C Middelfart, P V Rasmussen, G Gislason, M L Hansen
Publikováno v:
Europace. 25
Funding Acknowledgements Type of funding sources: None. Background Hypertrophic cardiomyopathy (HCM) is a common genetic cardiovascular disorder; however, detection rates remain low. While most patients are only mildly symptomatic, some develop serio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c3474d64f8422424c521276b2862deed
https://doi.org/10.1093/europace/euad122.228
https://doi.org/10.1093/europace/euad122.228
Autor:
J Toennesen, J L P Pallisgaard, P V R Rasmussen, M R Ruwald, C Z Zoerner, G G Gislason, M L H Hansen
Publikováno v:
European Heart Journal. 43
Introduction Guidelines recommend antiarrhythmic drugs (AAD) before ablation for atrial fibrillation (AF). However, recently published randomized clinical trials have demonstrated that ablation is more effective in maintaining sinus rhythm compared t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d54f572738f89f8a8b873203689dfbc
https://doi.org/10.1093/eurheartj/ehac544.531
https://doi.org/10.1093/eurheartj/ehac544.531
Autor:
C R Zoerner, J L Pallisgaard, A M Schjerning, J Toennesen, M K Jensen, G Gislason, M L Hansen
Publikováno v:
European Heart Journal. 43
Background The majority of patients with Hypertrophic cardiomyopathy (HCM) are mildly symptomatic or unaware of their condition, but some develop serious complications such as heart failure, atrial fibrillation (AF) as well as sudden cardiac death. P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::225915d190a2e6f2a6c55b1fa6abfb43
https://doi.org/10.1093/eurheartj/ehac544.1737
https://doi.org/10.1093/eurheartj/ehac544.1737
Autor:
N Nouhravesh, J Strange, J Toennesen, A Holt, C F Andersen, M H Jensen, A Al-Alak, M D'Souza, D Nielsen, K H Kragholm, E L Fosboel, M Schou, M K Lamberts
Publikováno v:
European Heart Journal. 43
Background Survival of patients with cardiovascular disease and cancers has increased due to improved treatments. However, the prognosis of acute coronary syndrome (ACS) in cancer patients is widely unknown, challenging clinical decision-making. Purp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4f1323b7fc782a611cbd26148209ef8
https://doi.org/10.1093/eurheartj/ehac544.1143
https://doi.org/10.1093/eurheartj/ehac544.1143
Publikováno v:
EP Europace. 24
Funding Acknowledgements Type of funding sources: Public hospital(s). Main funding source(s): Internal funding: Herlev-Gentofte Cardiovascular Research Department. Background Hypertrophic cardiomyopathy (HCM) can be associated with serious complicati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f16a38ae20d6ad74984d1018c246abea
https://doi.org/10.1093/europace/euac053.163
https://doi.org/10.1093/europace/euac053.163
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.